AC Immune SA (ACIU)
NASDAQ:ACIU

AC Immune SA (ACIU) Stock Price & Analysis

332 Followers

ACIU Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.68 - $4.93
Previous Close$2.4
Volume129.07K
Average Volume (3M)202.82K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)SFr.140.50M
Total Debt (Recent Filing)SFr.2.48M
Price to Earnings (P/E)-2.6
Beta<0.01
Next EarningsMar 21, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.94
Shares Outstanding83,413,498
R-Squared0.04
Standard Deviation0.16
10 Day Avg. Volume201,760
30 Day Avg. Volume202,821
Price to Book (P/B)1.27
Price to Sales (P/S)50.44
Price to Cash Flow (P/CF)8.90
P/FCF Ratio-3.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside429.66% Upside
Rating ConsensusModerate Buy
Alpha-0.02
Number of Analyst Covering2


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ACIU FAQ

What was AC Immune SA’s price range in the past 12 months?
AC Immune SA lowest stock price was $1.68 and its highest was $4.93 in the past 12 months.
    What is AC Immune SA’s market cap?
    Currently, no data Available
    When is AC Immune SA’s upcoming earnings report date?
    AC Immune SA’s upcoming earnings report date is Mar 21, 2023 which is in 53 days.
      How were AC Immune SA’s earnings last quarter?
      AC Immune SA released its earnings results on Oct 28, 2022. The company reported -$0.168 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.081.
        Is AC Immune SA overvalued?
        According to Wall Street analysts AC Immune SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does AC Immune SA pay dividends?
          AC Immune SA does not currently pay dividends.
          What is AC Immune SA’s EPS estimate?
          AC Immune SA’s EPS estimate is -$0.27.
            How many shares outstanding does AC Immune SA have?
            AC Immune SA has 83,552,290 shares outstanding.
              What happened to AC Immune SA’s price movement after its last earnings report?
              AC Immune SA reported an EPS of -$0.168 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went down -6.452%.
                Which hedge fund is a major shareholder of AC Immune SA?
                Among the largest hedge funds holding AC Immune SA’s share is Platinum Investment Management. It holds AC Immune SA’s shares valued at 3M.

                  ---

                  AC Immune SA Stock Smart Score

                  5
                  Neutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -43.12%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -40.40%
                  Trailing 12-Months
                  Asset Growth
                  -4.22%
                  Trailing 12-Months
                  The AC Immune SA stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  AC Immune SA

                  AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  MoonLake Immunotherapeutics
                  VectivBio Holding
                  ADC Therapeutics
                  Crispr Therapeutics AG

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis